Method Specific

Intrauterine Contraception

Progestogen-only Implants

CEU Statement: Intravascular insertion of Nexplanon® - June 2016

01 June 2016

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD to healthcare professionals in the UK regarding a small number of reports of Nexplanon contraceptive implants inadvertently inserted into blood vessels.

This document is up-to-date

Progestogen-only Injectables

Combined Hormonal Contraception

CEU Statement: Response to new reports of link between COC and Glaucoma (November 2013)

01 November 2013

Following a presentation at the annual meeting of the American Academy of Ophthalmology a number of media reports have reported a possible link between use of combined oral contraception (COC) and glaucoma. There is limited data investigating combined hormonal contraceptives on glaucoma. One cohort study suggested that 5 or more years of COC use was associated with a 25% increase in the risk of glaucoma. Two UK cohort studies did not find consistent evidence of an increased risk.

This document is up-to-date

CEU Statement: Strengthening of Warnings about use of Dianette and other brands of co-cyprindiol (June 2013)

01 June 2013

Following a recent safety review, a letter has been issued to healthcare professionals from the manufacturers of Dianette® and other cyproterone acetate 2 mg/ ethinylestradiol 35 mcg (co-cyprindiol) products. The review by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) followed concerns about the risk of thrombosis associated with co-cyprindiol. With the agreement of the EMA and Medicines and Healthcare products Regulatory Authority (MHRA), a letter has been issued to raise awareness of the thrombosis risks and the outcome of the review.

This document is up-to-date

Barrier Methods

Male and Female Sterilisation

CEU Statement: Response to the BMJ paper by Mao et. al. (October 2015)

01 October 2015

A large observational study from the United States found that the risk of unintended pregnancy after Essure sterilisation was similar to that after surgical sterilisation. However just over 2% of women who had Essure sterilisation required a further operation related to the sterilisation procedure within a year.

This document is up-to-date

Long-Acting Reversible Contraception (LARC)